Caris Life Sciences, Inc. (CAI) 10-Year Financial Performance & Capital Metrics

CAI • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

AboutCaris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.Show more

Revenue $412M +34.7%
EBITDA -$208M +23.0%
Net Income -$282M +17.4%
EPS (Diluted) -2.70 -48.4%
Gross Margin 43.37% +48.6%
EBITDA Margin -50.5% +42.9%
Operating Margin -62.37% +40.3%
Net Margin -68.38% +38.7%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -5.14 +49.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Efficient asset utilization: 1.2x turnover

✗Weaknesses

✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y6.86%

5Y-0.94%

3Y11.93%

TTM100.08%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-195.67%

EPS CAGR

10Y-

5Y-

3Y-

TTM-88.93%

ROCE

10Y Avg-16.06%

5Y Avg-37.22%

3Y Avg-65.6%

Latest-103.66%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	227.59M	249.67M	294.35M	348.39M	432.1M	416.54M	294.01M	258.49M	306.13M	412.26M
Revenue Growth %	0.07%	0.1%	0.18%	0.18%	0.24%	-0.04%	-0.29%	-0.12%	0.18%	0.35%
Cost of Goods Sold+	77.98M	123.76M	156.86M	179.11M	218.47M	216.03M	109.86M	178.46M	216.82M	233.48M
COGS % of Revenue	0.34%	0.5%	0.53%	0.51%	0.51%	0.52%	0.37%	0.69%	0.71%	0.57%
Gross Profit+	149.61M	125.91M	137.5M	169.29M	213.63M	200.51M	184.16M	80.02M	89.31M	178.78M
Gross Margin %	0.66%	0.5%	0.47%	0.49%	0.49%	0.48%	0.63%	0.31%	0.29%	0.43%
Gross Profit Growth %	0.03%	-0.16%	0.09%	0.23%	0.26%	-0.06%	-0.08%	-0.57%	0.12%	1%
Operating Expenses+	52.58M	57.81M	71.54M	63.62M	64.85M	70.23M	45.07M	395.78M	408.86M	435.9M
OpEx % of Revenue	0.23%	0.23%	0.24%	0.18%	0.15%	0.17%	0.15%	1.53%	1.34%	1.06%
Selling, General & Admin	0	27.62M	35.68M	42.7M	50.3M	52.7M	27.31M	294.51M	291.48M	321.86M
SG&A % of Revenue	-	0.11%	0.12%	0.12%	0.12%	0.13%	0.09%	1.14%	0.95%	0.78%
Research & Development	0	0	0	0	0	0	0	101.27M	116.88M	113.92M
R&D % of Revenue	-	-	-	-	-	-	-	0.39%	0.38%	0.28%
Other Operating Expenses	52.58M	30.19M	35.86M	20.92M	14.54M	17.53M	17.76M	0	500K	128K
Operating Income+	97.03M	68.09M	65.96M	105.67M	148.78M	130.28M	139.09M	-315.76M	-319.55M	-257.12M
Operating Margin %	0.43%	0.27%	0.22%	0.3%	0.34%	0.31%	0.47%	-1.22%	-1.04%	-0.62%
Operating Income Growth %	-0.04%	-0.3%	-0.03%	0.6%	0.41%	-0.12%	0.07%	-3.27%	-0.01%	0.2%
EBITDA+	175.87M	182.33M	172.64M	218.93M	272.26M	244.21M	249.74M	-267.5M	-270.55M	-208.21M
EBITDA Margin %	0.77%	0.73%	0.59%	0.63%	0.63%	0.59%	0.85%	-1.03%	-0.88%	-0.51%
EBITDA Growth %	0.04%	0.04%	-0.05%	0.27%	0.24%	-0.1%	0.02%	-2.07%	-0.01%	0.23%
D&A (Non-Cash Add-back)	78.83M	114.23M	106.68M	113.26M	123.48M	113.93M	110.65M	48.25M	49M	48.91M
EBIT	102.79M	67.26M	52.63M	110.25M	159.83M	134.37M	143.81M	-294.15M	-309.81M	-231.87M
Net Interest Income+	-35.2M	0	0	0	0	-79.16M	-61.56M	-25.73M	-20.35M	-42.9M
Interest Income	7K	0	0	0	0	0	0	947K	11.26M	7.12M
Interest Expense	35.21M	36.03M	42.75M	53.05M	78.34M	79.16M	61.56M	26.68M	31.61M	50.02M
Other Income/Expense	-29.46M	-36.87M	-56.08M	-48.47M	-67.3M	0	-109.55M	-5.07M	-21.86M	-24.77M
Pretax Income+	67.58M	31.22M	9.88M	57.2M	81.48M	55.21M	29.53M	-320.83M	-341.42M	-281.89M
Pretax Margin %	0.3%	0.13%	0.03%	0.16%	0.19%	0.13%	0.1%	-1.24%	-1.12%	-0.68%
Income Tax+	7.19M	4.25M	3.84M	-14.86M	2.89M	4.19M	1.8M	0	0	0
Effective Tax Rate %	0.89%	0.86%	0.61%	1.26%	0.96%	0.56%	0.94%	1%	1%	1%
Net Income+	60.27M	26.84M	6M	72.06M	78.6M	31.01M	27.73M	-320.83M	-341.42M	-281.89M
Net Margin %	0.26%	0.11%	0.02%	0.21%	0.18%	0.07%	0.09%	-1.24%	-1.12%	-0.68%
Net Income Growth %	-0.06%	-0.55%	-0.78%	11.02%	0.09%	-0.61%	-0.11%	-12.57%	-0.06%	0.17%
Net Income (Continuing)	60.27M	26.84M	6M	72.06M	78.6M	31.01M	27.73M	-320.83M	-341.42M	-281.89M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	2.85	1.28	0.31	3.68	3.97	1.72	1.55	-1.57	-1.82	-2.70
EPS Growth %	0.01%	-0.55%	-0.76%	10.87%	0.08%	-0.57%	-0.1%	-2.01%	-0.16%	-0.48%
EPS (Basic)	2.91	1.29	0.31	3.74	3.97	1.72	1.55	-1.57	-1.82	-2.70
Diluted Shares Outstanding	21.16M	20.99M	19.39M	19.61M	19.82M	18.01M	17.95M	254.79M	254.66M	254.66M
Basic Shares Outstanding	20.73M	20.77M	19.32M	19.25M	19.82M	18.01M	17.95M	254.79M	254.66M	254.66M
Dividend Payout Ratio	-	-	-	-	0.04%	0.28%	0.64%	-	-	-

Balance Sheet

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	144.8M	144.11M	135.15M	140.34M	220.02M	499.13M	214.66M	516.04M	242.61M	215.73M
Cash & Short-Term Investments	71.97M	73.71M	66.09M	65.48M	121.29M	46.46M	132.54M	409.62M	121.59M	66.15M
Cash Only	53.82M	52.55M	46.13M	35.42M	45.31M	46.46M	53.55M	107.19M	56.4M	63.95M
Short-Term Investments	18.15M	21.16M	19.96M	30.06M	75.97M	0	78.99M	302.43M	65.18M	2.2M
Accounts Receivable	76.17M	76.44M	83.7M	100.66M	171.92M	159.68M	144.3M	40.23M	55.3M	88.24M
Days Sales Outstanding	122.16	111.75	103.79	105.46	145.22	139.92	179.14	56.8	65.93	78.13
Inventory	0	0	0	0	0	0	0	46.96M	49M	39.57M
Days Inventory Outstanding	-	-	-	-	-	-	-	96.04	82.49	61.86
Other Current Assets	-3.34M	-6.04M	-14.64M	-25.8M	-73.19M	292.98M	-62.18M	5.88M	4.96M	8.2M
Total Non-Current Assets+	1.65B	1.84B	1.92B	2.29B	2.79B	2.4B	2.4B	201.38M	170.29M	128M
Property, Plant & Equipment	1.57B	1.75B	1.81B	2.01B	2.27B	1.82B	1.78B	138.05M	147.51M	102.77M
Fixed Asset Turnover	0.15x	0.14x	0.16x	0.17x	0.19x	0.23x	0.17x	1.87x	2.08x	4.01x
Goodwill	0	2.9M	15.79M	15.79M	15.79M	15.79M	0	19.34M	19.34M	19.34M
Intangible Assets	273K	1.22M	9.69M	7.72M	5.73M	4.12M	0	0	0	0
Long-Term Investments	76.81M	82.21M	80.58M	246.45M	473.79M	495.49M	0	0	0	0
Other Non-Current Assets	8.23M	7.21M	7.15M	14.8M	31.05M	66.5M	616.65M	43.98M	3.43M	5.89M
Total Assets+	1.8B	1.99B	2.06B	2.43B	3.01B	2.9B	2.61B	717.42M	412.9M	343.73M
Asset Turnover	0.13x	0.13x	0.14x	0.14x	0.14x	0.14x	0.11x	0.36x	0.74x	1.20x
Asset Growth %	0.07%	0.11%	0.03%	0.18%	0.24%	-0.04%	-0.1%	-0.73%	-0.42%	-0.17%
Total Current Liabilities+	249.19M	217.88M	164.01M	259.93M	425.53M	287.41M	320.25M	136.91M	95.14M	165.42M
Accounts Payable	8.41M	11.96M	13.8M	7.83M	7.37M	7.29M	3.67M	27.27M	26.68M	27.79M
Days Payables Outstanding	39.39	35.28	32.12	15.96	12.31	12.32	12.18	55.77	44.91	43.45
Short-Term Debt	204.21M	172.42M	95.53M	132.05M	311.38M	218.09M	183.45M	52.79M	167K	60M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	29.39M	21.51M	44.06M	112.24M	99.21M	55.62M	130.11M	22.65M	22.13M	30.69M
Current Ratio	0.58x	0.66x	0.82x	0.54x	0.52x	1.74x	0.67x	3.77x	2.55x	1.30x
Quick Ratio	0.58x	0.66x	0.82x	0.54x	0.52x	1.74x	0.67x	3.43x	2.04x	1.06x
Cash Conversion Cycle	-	-	-	-	-	-	-	97.07	103.5	96.55
Total Non-Current Liabilities+	1.1B	1.31B	1.43B	1.61B	1.89B	1.92B	1.59B	2.28B	2.46B	2.68B
Long-Term Debt	1.06B	1.26B	1.38B	1.57B	1.85B	1.88B	1.56B	169.57M	166.11M	319.19M
Capital Lease Obligations	0	0	0	0	0	0	0	44.2M	44.41M	38.89M
Deferred Tax Liabilities	43.42M	48.2M	51.8M	35.85M	38.32M	35.38M	24.44M	0	0	0
Other Non-Current Liabilities	1.57M	0	2.12M	0	0	5.62M	3.42M	2.07B	2.25B	2.32B
Total Liabilities	1.35B	1.53B	1.6B	1.87B	2.31B	2.21B	1.91B	2.42B	2.56B	2.84B
Total Debt+	1.26B	1.43B	1.48B	1.7B	2.16B	2.1B	1.75B	270.87M	217.27M	424.26M
Net Debt	1.21B	1.38B	1.43B	1.67B	2.11B	2.05B	1.69B	163.68M	160.87M	360.31M
Debt / Equity	2.86x	3.11x	3.23x	3.02x	3.08x	3.03x	2.49x	-	-	-
Debt / EBITDA	7.18x	7.85x	8.55x	7.78x	7.93x	8.59x	6.99x	-	-	-
Net Debt / EBITDA	6.88x	7.56x	8.28x	7.62x	7.76x	8.40x	6.78x	-	-	-
Interest Coverage	2.76x	1.89x	1.54x	1.99x	1.90x	1.65x	2.26x	-11.83x	-10.11x	-5.14x
Total Equity+	0	0	457.5M	563.85M	701.13M	693.24M	702.24M	-1.7B	-2.14B	-2.5B
Equity Growth %	-	-	-	0.23%	0.24%	-0.01%	0.01%	-3.42%	-0.26%	-0.16%
Book Value per Share	20.90	21.93	23.59	28.76	35.38	38.49	39.12	-6.68	-8.42	-9.81
Total Shareholders' Equity	442.12M	460.34M	457.5M	563.85M	701.13M	693.24M	702.24M	-1.7B	-2.14B	-2.5B
Common Stock	2K	2K	2K	2K	2K	2K	2K	138K	38K	38K
Retained Earnings	292.9M	319.74M	324.58M	397.64M	471.11M	493.29M	503.32M	-1.68B	-2.12B	-2.47B
Treasury Stock	0	0	0	0	0	0	0	-330K	-330K	-330K
Accumulated OCI	-5.68M	-7.92M	-8.13M	-6.12M	-6.51M	-6.63M	-5.74M	1.7M	218K	210K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	139.69M	147.37M	129.26M	155.19M	179.77M	254M	277.02M	-285.71M	-276.1M	-245.2M
Operating CF Margin %	0.61%	0.59%	0.44%	0.45%	0.42%	0.61%	0.94%	-1.11%	-0.9%	-0.59%
Operating CF Growth %	0.12%	0.05%	-0.12%	0.2%	0.16%	0.41%	0.09%	-2.03%	0.03%	0.11%
Net Income	60.27M	26.84M	6M	72.06M	78.6M	31.01M	27.73M	-320.83M	-341.42M	-281.89M
Depreciation & Amortization	78.83M	114.23M	106.68M	113.26M	123.48M	113.93M	110.65M	48.25M	49M	48.91M
Stock-Based Compensation	1.89M	1.92M	1.73M	2.09M	2.87M	2.76M	1.77M	22.9M	15.24M	18.64M
Deferred Taxes	2.17M	4.97M	1.14M	-14.95M	2.47M	3.73M	1.37M	0	0	0
Other Non-Cash Items	74.94M	-31.21M	-31.21M	73.47M	58.28M	-314.67M	452.8M	-13.78M	8.2M	-1.8M
Working Capital Changes	-78.42M	30.62M	44.92M	-90.74M	-85.92M	417.23M	-317.31M	-22.26M	-7.13M	-29.07M
Change in Receivables	-6.4M	4.73M	-1.8M	-7.8M	-19.27M	3.86M	11M	-11.9M	-15.08M	-33.82M
Change in Inventory	29.33M	103.32M	72M	38.86M	138.85M	0	0	-11.1M	-4.43M	5.46M
Change in Payables	3.05M	-3.65M	3.57M	-2.21M	15K	0	0	8.91M	7.17M	-226K
Cash from Investing+	-225.35M	-305.25M	-181.6M	-411.75M	-663.34M	-271.87M	-33.97M	-282.99M	214.77M	52.93M
Capital Expenditures	-307.31M	-389.41M	-251.25M	-502.18M	-812.84M	-319.14M	-219.45M	-42.26M	-22.32M	-8.44M
CapEx % of Revenue	1.35%	1.56%	0.85%	1.44%	1.88%	0.77%	0.75%	0.16%	0.07%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	65.64M	66.15M	66.07M	66.36M	106.15M	47.27M	185.48M	0	0	0
Cash from Financing+	95.14M	156.54M	46.6M	245.63M	512.35M	-108.48M	-249.88M	10.45M	10.13M	200.29M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	-3.26M	-8.83M	-17.71M	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	95.14M	156.54M	46.6M	245.63M	515.61M	-99.65M	-232.18M	11.41M	-435K	471K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-167.62M	-242.04M	-121.99M	-346.98M	-633.07M	-65.14M	57.57M	-327.96M	-298.42M	-253.64M
FCF Margin %	-0.74%	-0.97%	-0.41%	-1%	-1.47%	-0.16%	0.2%	-1.27%	-0.97%	-0.62%
FCF Growth %	0.11%	-0.44%	0.5%	-1.84%	-0.82%	0.9%	1.88%	-6.7%	0.09%	0.15%
FCF per Share	-7.92	-11.53	-6.29	-17.70	-31.94	-3.62	3.21	-1.29	-1.17	-1.00
FCF Conversion (FCF/Net Income)	2.32x	5.49x	21.55x	2.15x	2.29x	8.19x	9.99x	0.89x	0.81x	0.87x
Interest Paid	0	0	0	0	0	0	0	24.24M	15.78M	49.02M
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2014	2015	2016	2017	2018	2019	2020	2022	2023	2024
Return on Equity (ROE)	14.07%	5.95%	1.31%	14.11%	12.43%	4.45%	3.97%	-	-	-
Return on Invested Capital (ROIC)	4.61%	2.93%	2.65%	3.85%	4.42%	3.51%	4.06%	-55.33%	-	-
Gross Margin	65.74%	50.43%	46.71%	48.59%	49.44%	48.14%	62.64%	30.96%	29.17%	43.37%
Net Margin	26.48%	10.75%	2.04%	20.68%	18.19%	7.44%	9.43%	-124.12%	-111.53%	-68.38%
Debt / Equity	2.86x	3.11x	3.23x	3.02x	3.08x	3.03x	2.49x	-	-	-
Interest Coverage	2.76x	1.89x	1.54x	1.99x	1.90x	1.65x	2.26x	-11.83x	-10.11x	-5.14x
FCF Conversion	2.32x	5.49x	21.55x	2.15x	2.29x	8.19x	9.99x	0.89x	0.81x	0.87x
Revenue Growth	7.15%	9.7%	17.9%	18.36%	24.03%	-3.6%	-29.42%	-12.08%	18.43%	34.67%

Frequently Asked Questions

Growth & Financials

Caris Life Sciences, Inc. (CAI) reported $620.0M in revenue for fiscal year 2024. This represents a 696% increase from $77.9M in 2010.

Caris Life Sciences, Inc. (CAI) grew revenue by 34.7% over the past year. This is strong growth.

Caris Life Sciences, Inc. (CAI) reported a net loss of $98.9M for fiscal year 2024.

Dividend & Returns

Caris Life Sciences, Inc. (CAI) had negative free cash flow of $420.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Caris Life Sciences, Inc. (CAI) 10-Year Financial Performance & Capital Metrics

CAI • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

Revenue $412M +34.7%
EBITDA -$208M +23.0%
Net Income -$282M +17.4%
EPS (Diluted) -2.70 -48.4%
Gross Margin 43.37% +48.6%
EBITDA Margin -50.5% +42.9%
Operating Margin -62.37% +40.3%
Net Margin -68.38% +38.7%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -5.14 +49.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Efficient asset utilization: 1.2x turnover

✗Weaknesses

✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y6.86%

5Y-0.94%

3Y11.93%

TTM100.08%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-195.67%

EPS CAGR

10Y-

5Y-

3Y-

TTM-88.93%

ROCE

10Y Avg-16.06%

5Y Avg-37.22%

3Y Avg-65.6%

Latest-103.66%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	227.59M	249.67M	294.35M	348.39M	432.1M	416.54M	294.01M	258.49M	306.13M	412.26M
Revenue Growth %	0.07%	0.1%	0.18%	0.18%	0.24%	-0.04%	-0.29%	-0.12%	0.18%	0.35%
Cost of Goods Sold+	77.98M	123.76M	156.86M	179.11M	218.47M	216.03M	109.86M	178.46M	216.82M	233.48M
COGS % of Revenue	0.34%	0.5%	0.53%	0.51%	0.51%	0.52%	0.37%	0.69%	0.71%	0.57%
Gross Profit+	149.61M	125.91M	137.5M	169.29M	213.63M	200.51M	184.16M	80.02M	89.31M	178.78M
Gross Margin %	0.66%	0.5%	0.47%	0.49%	0.49%	0.48%	0.63%	0.31%	0.29%	0.43%
Gross Profit Growth %	0.03%	-0.16%	0.09%	0.23%	0.26%	-0.06%	-0.08%	-0.57%	0.12%	1%
Operating Expenses+	52.58M	57.81M	71.54M	63.62M	64.85M	70.23M	45.07M	395.78M	408.86M	435.9M
OpEx % of Revenue	0.23%	0.23%	0.24%	0.18%	0.15%	0.17%	0.15%	1.53%	1.34%	1.06%
Selling, General & Admin	0	27.62M	35.68M	42.7M	50.3M	52.7M	27.31M	294.51M	291.48M	321.86M
SG&A % of Revenue	-	0.11%	0.12%	0.12%	0.12%	0.13%	0.09%	1.14%	0.95%	0.78%
Research & Development	0	0	0	0	0	0	0	101.27M	116.88M	113.92M
R&D % of Revenue	-	-	-	-	-	-	-	0.39%	0.38%	0.28%
Other Operating Expenses	52.58M	30.19M	35.86M	20.92M	14.54M	17.53M	17.76M	0	500K	128K
Operating Income+	97.03M	68.09M	65.96M	105.67M	148.78M	130.28M	139.09M	-315.76M	-319.55M	-257.12M
Operating Margin %	0.43%	0.27%	0.22%	0.3%	0.34%	0.31%	0.47%	-1.22%	-1.04%	-0.62%
Operating Income Growth %	-0.04%	-0.3%	-0.03%	0.6%	0.41%	-0.12%	0.07%	-3.27%	-0.01%	0.2%
EBITDA+	175.87M	182.33M	172.64M	218.93M	272.26M	244.21M	249.74M	-267.5M	-270.55M	-208.21M
EBITDA Margin %	0.77%	0.73%	0.59%	0.63%	0.63%	0.59%	0.85%	-1.03%	-0.88%	-0.51%
EBITDA Growth %	0.04%	0.04%	-0.05%	0.27%	0.24%	-0.1%	0.02%	-2.07%	-0.01%	0.23%
D&A (Non-Cash Add-back)	78.83M	114.23M	106.68M	113.26M	123.48M	113.93M	110.65M	48.25M	49M	48.91M
EBIT	102.79M	67.26M	52.63M	110.25M	159.83M	134.37M	143.81M	-294.15M	-309.81M	-231.87M
Net Interest Income+	-35.2M	0	0	0	0	-79.16M	-61.56M	-25.73M	-20.35M	-42.9M
Interest Income	7K	0	0	0	0	0	0	947K	11.26M	7.12M
Interest Expense	35.21M	36.03M	42.75M	53.05M	78.34M	79.16M	61.56M	26.68M	31.61M	50.02M
Other Income/Expense	-29.46M	-36.87M	-56.08M	-48.47M	-67.3M	0	-109.55M	-5.07M	-21.86M	-24.77M
Pretax Income+	67.58M	31.22M	9.88M	57.2M	81.48M	55.21M	29.53M	-320.83M	-341.42M	-281.89M
Pretax Margin %	0.3%	0.13%	0.03%	0.16%	0.19%	0.13%	0.1%	-1.24%	-1.12%	-0.68%
Income Tax+	7.19M	4.25M	3.84M	-14.86M	2.89M	4.19M	1.8M	0	0	0
Effective Tax Rate %	0.89%	0.86%	0.61%	1.26%	0.96%	0.56%	0.94%	1%	1%	1%
Net Income+	60.27M	26.84M	6M	72.06M	78.6M	31.01M	27.73M	-320.83M	-341.42M	-281.89M
Net Margin %	0.26%	0.11%	0.02%	0.21%	0.18%	0.07%	0.09%	-1.24%	-1.12%	-0.68%
Net Income Growth %	-0.06%	-0.55%	-0.78%	11.02%	0.09%	-0.61%	-0.11%	-12.57%	-0.06%	0.17%
Net Income (Continuing)	60.27M	26.84M	6M	72.06M	78.6M	31.01M	27.73M	-320.83M	-341.42M	-281.89M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	2.85	1.28	0.31	3.68	3.97	1.72	1.55	-1.57	-1.82	-2.70
EPS Growth %	0.01%	-0.55%	-0.76%	10.87%	0.08%	-0.57%	-0.1%	-2.01%	-0.16%	-0.48%
EPS (Basic)	2.91	1.29	0.31	3.74	3.97	1.72	1.55	-1.57	-1.82	-2.70
Diluted Shares Outstanding	21.16M	20.99M	19.39M	19.61M	19.82M	18.01M	17.95M	254.79M	254.66M	254.66M
Basic Shares Outstanding	20.73M	20.77M	19.32M	19.25M	19.82M	18.01M	17.95M	254.79M	254.66M	254.66M
Dividend Payout Ratio	-	-	-	-	0.04%	0.28%	0.64%	-	-	-

Balance Sheet

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	144.8M	144.11M	135.15M	140.34M	220.02M	499.13M	214.66M	516.04M	242.61M	215.73M
Cash & Short-Term Investments	71.97M	73.71M	66.09M	65.48M	121.29M	46.46M	132.54M	409.62M	121.59M	66.15M
Cash Only	53.82M	52.55M	46.13M	35.42M	45.31M	46.46M	53.55M	107.19M	56.4M	63.95M
Short-Term Investments	18.15M	21.16M	19.96M	30.06M	75.97M	0	78.99M	302.43M	65.18M	2.2M
Accounts Receivable	76.17M	76.44M	83.7M	100.66M	171.92M	159.68M	144.3M	40.23M	55.3M	88.24M
Days Sales Outstanding	122.16	111.75	103.79	105.46	145.22	139.92	179.14	56.8	65.93	78.13
Inventory	0	0	0	0	0	0	0	46.96M	49M	39.57M
Days Inventory Outstanding	-	-	-	-	-	-	-	96.04	82.49	61.86
Other Current Assets	-3.34M	-6.04M	-14.64M	-25.8M	-73.19M	292.98M	-62.18M	5.88M	4.96M	8.2M
Total Non-Current Assets+	1.65B	1.84B	1.92B	2.29B	2.79B	2.4B	2.4B	201.38M	170.29M	128M
Property, Plant & Equipment	1.57B	1.75B	1.81B	2.01B	2.27B	1.82B	1.78B	138.05M	147.51M	102.77M
Fixed Asset Turnover	0.15x	0.14x	0.16x	0.17x	0.19x	0.23x	0.17x	1.87x	2.08x	4.01x
Goodwill	0	2.9M	15.79M	15.79M	15.79M	15.79M	0	19.34M	19.34M	19.34M
Intangible Assets	273K	1.22M	9.69M	7.72M	5.73M	4.12M	0	0	0	0
Long-Term Investments	76.81M	82.21M	80.58M	246.45M	473.79M	495.49M	0	0	0	0
Other Non-Current Assets	8.23M	7.21M	7.15M	14.8M	31.05M	66.5M	616.65M	43.98M	3.43M	5.89M
Total Assets+	1.8B	1.99B	2.06B	2.43B	3.01B	2.9B	2.61B	717.42M	412.9M	343.73M
Asset Turnover	0.13x	0.13x	0.14x	0.14x	0.14x	0.14x	0.11x	0.36x	0.74x	1.20x
Asset Growth %	0.07%	0.11%	0.03%	0.18%	0.24%	-0.04%	-0.1%	-0.73%	-0.42%	-0.17%
Total Current Liabilities+	249.19M	217.88M	164.01M	259.93M	425.53M	287.41M	320.25M	136.91M	95.14M	165.42M
Accounts Payable	8.41M	11.96M	13.8M	7.83M	7.37M	7.29M	3.67M	27.27M	26.68M	27.79M
Days Payables Outstanding	39.39	35.28	32.12	15.96	12.31	12.32	12.18	55.77	44.91	43.45
Short-Term Debt	204.21M	172.42M	95.53M	132.05M	311.38M	218.09M	183.45M	52.79M	167K	60M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	29.39M	21.51M	44.06M	112.24M	99.21M	55.62M	130.11M	22.65M	22.13M	30.69M
Current Ratio	0.58x	0.66x	0.82x	0.54x	0.52x	1.74x	0.67x	3.77x	2.55x	1.30x
Quick Ratio	0.58x	0.66x	0.82x	0.54x	0.52x	1.74x	0.67x	3.43x	2.04x	1.06x
Cash Conversion Cycle	-	-	-	-	-	-	-	97.07	103.5	96.55
Total Non-Current Liabilities+	1.1B	1.31B	1.43B	1.61B	1.89B	1.92B	1.59B	2.28B	2.46B	2.68B
Long-Term Debt	1.06B	1.26B	1.38B	1.57B	1.85B	1.88B	1.56B	169.57M	166.11M	319.19M
Capital Lease Obligations	0	0	0	0	0	0	0	44.2M	44.41M	38.89M
Deferred Tax Liabilities	43.42M	48.2M	51.8M	35.85M	38.32M	35.38M	24.44M	0	0	0
Other Non-Current Liabilities	1.57M	0	2.12M	0	0	5.62M	3.42M	2.07B	2.25B	2.32B
Total Liabilities	1.35B	1.53B	1.6B	1.87B	2.31B	2.21B	1.91B	2.42B	2.56B	2.84B
Total Debt+	1.26B	1.43B	1.48B	1.7B	2.16B	2.1B	1.75B	270.87M	217.27M	424.26M
Net Debt	1.21B	1.38B	1.43B	1.67B	2.11B	2.05B	1.69B	163.68M	160.87M	360.31M
Debt / Equity	2.86x	3.11x	3.23x	3.02x	3.08x	3.03x	2.49x	-	-	-
Debt / EBITDA	7.18x	7.85x	8.55x	7.78x	7.93x	8.59x	6.99x	-	-	-
Net Debt / EBITDA	6.88x	7.56x	8.28x	7.62x	7.76x	8.40x	6.78x	-	-	-
Interest Coverage	2.76x	1.89x	1.54x	1.99x	1.90x	1.65x	2.26x	-11.83x	-10.11x	-5.14x
Total Equity+	0	0	457.5M	563.85M	701.13M	693.24M	702.24M	-1.7B	-2.14B	-2.5B
Equity Growth %	-	-	-	0.23%	0.24%	-0.01%	0.01%	-3.42%	-0.26%	-0.16%
Book Value per Share	20.90	21.93	23.59	28.76	35.38	38.49	39.12	-6.68	-8.42	-9.81
Total Shareholders' Equity	442.12M	460.34M	457.5M	563.85M	701.13M	693.24M	702.24M	-1.7B	-2.14B	-2.5B
Common Stock	2K	2K	2K	2K	2K	2K	2K	138K	38K	38K
Retained Earnings	292.9M	319.74M	324.58M	397.64M	471.11M	493.29M	503.32M	-1.68B	-2.12B	-2.47B
Treasury Stock	0	0	0	0	0	0	0	-330K	-330K	-330K
Accumulated OCI	-5.68M	-7.92M	-8.13M	-6.12M	-6.51M	-6.63M	-5.74M	1.7M	218K	210K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	139.69M	147.37M	129.26M	155.19M	179.77M	254M	277.02M	-285.71M	-276.1M	-245.2M
Operating CF Margin %	0.61%	0.59%	0.44%	0.45%	0.42%	0.61%	0.94%	-1.11%	-0.9%	-0.59%
Operating CF Growth %	0.12%	0.05%	-0.12%	0.2%	0.16%	0.41%	0.09%	-2.03%	0.03%	0.11%
Net Income	60.27M	26.84M	6M	72.06M	78.6M	31.01M	27.73M	-320.83M	-341.42M	-281.89M
Depreciation & Amortization	78.83M	114.23M	106.68M	113.26M	123.48M	113.93M	110.65M	48.25M	49M	48.91M
Stock-Based Compensation	1.89M	1.92M	1.73M	2.09M	2.87M	2.76M	1.77M	22.9M	15.24M	18.64M
Deferred Taxes	2.17M	4.97M	1.14M	-14.95M	2.47M	3.73M	1.37M	0	0	0
Other Non-Cash Items	74.94M	-31.21M	-31.21M	73.47M	58.28M	-314.67M	452.8M	-13.78M	8.2M	-1.8M
Working Capital Changes	-78.42M	30.62M	44.92M	-90.74M	-85.92M	417.23M	-317.31M	-22.26M	-7.13M	-29.07M
Change in Receivables	-6.4M	4.73M	-1.8M	-7.8M	-19.27M	3.86M	11M	-11.9M	-15.08M	-33.82M
Change in Inventory	29.33M	103.32M	72M	38.86M	138.85M	0	0	-11.1M	-4.43M	5.46M
Change in Payables	3.05M	-3.65M	3.57M	-2.21M	15K	0	0	8.91M	7.17M	-226K
Cash from Investing+	-225.35M	-305.25M	-181.6M	-411.75M	-663.34M	-271.87M	-33.97M	-282.99M	214.77M	52.93M
Capital Expenditures	-307.31M	-389.41M	-251.25M	-502.18M	-812.84M	-319.14M	-219.45M	-42.26M	-22.32M	-8.44M
CapEx % of Revenue	1.35%	1.56%	0.85%	1.44%	1.88%	0.77%	0.75%	0.16%	0.07%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	65.64M	66.15M	66.07M	66.36M	106.15M	47.27M	185.48M	0	0	0
Cash from Financing+	95.14M	156.54M	46.6M	245.63M	512.35M	-108.48M	-249.88M	10.45M	10.13M	200.29M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	-3.26M	-8.83M	-17.71M	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	95.14M	156.54M	46.6M	245.63M	515.61M	-99.65M	-232.18M	11.41M	-435K	471K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-167.62M	-242.04M	-121.99M	-346.98M	-633.07M	-65.14M	57.57M	-327.96M	-298.42M	-253.64M
FCF Margin %	-0.74%	-0.97%	-0.41%	-1%	-1.47%	-0.16%	0.2%	-1.27%	-0.97%	-0.62%
FCF Growth %	0.11%	-0.44%	0.5%	-1.84%	-0.82%	0.9%	1.88%	-6.7%	0.09%	0.15%
FCF per Share	-7.92	-11.53	-6.29	-17.70	-31.94	-3.62	3.21	-1.29	-1.17	-1.00
FCF Conversion (FCF/Net Income)	2.32x	5.49x	21.55x	2.15x	2.29x	8.19x	9.99x	0.89x	0.81x	0.87x
Interest Paid	0	0	0	0	0	0	0	24.24M	15.78M	49.02M
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2014	2015	2016	2017	2018	2019	2020	2022	2023	2024
Return on Equity (ROE)	14.07%	5.95%	1.31%	14.11%	12.43%	4.45%	3.97%	-	-	-
Return on Invested Capital (ROIC)	4.61%	2.93%	2.65%	3.85%	4.42%	3.51%	4.06%	-55.33%	-	-
Gross Margin	65.74%	50.43%	46.71%	48.59%	49.44%	48.14%	62.64%	30.96%	29.17%	43.37%
Net Margin	26.48%	10.75%	2.04%	20.68%	18.19%	7.44%	9.43%	-124.12%	-111.53%	-68.38%
Debt / Equity	2.86x	3.11x	3.23x	3.02x	3.08x	3.03x	2.49x	-	-	-
Interest Coverage	2.76x	1.89x	1.54x	1.99x	1.90x	1.65x	2.26x	-11.83x	-10.11x	-5.14x
FCF Conversion	2.32x	5.49x	21.55x	2.15x	2.29x	8.19x	9.99x	0.89x	0.81x	0.87x
Revenue Growth	7.15%	9.7%	17.9%	18.36%	24.03%	-3.6%	-29.42%	-12.08%	18.43%	34.67%

Frequently Asked Questions

Growth & Financials

Caris Life Sciences, Inc. (CAI) reported $620.0M in revenue for fiscal year 2024. This represents a 696% increase from $77.9M in 2010.

Caris Life Sciences, Inc. (CAI) grew revenue by 34.7% over the past year. This is strong growth.

Caris Life Sciences, Inc. (CAI) reported a net loss of $98.9M for fiscal year 2024.

Dividend & Returns

Caris Life Sciences, Inc. (CAI) had negative free cash flow of $420.4M in fiscal year 2024, likely due to heavy capital investments.